Found 240 results
[ Author(Desc)] Title Type Year
Filters: First Letter Of Title is C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
M. Cairo, Cohen, G., Wagner, E., Fraser, J., Jensen, L., Carter, S., Kernan, N., and Kurtzberg, J., Cord Blood (CB) Hematopoietic Progenitor Cell (HPC) Characterization and Correlation with Ethnicity: A Report From The COBLT Study, 2004.
M. Cairo, Wagner, E., Cohen, G., Fraser, J., Jensen, L., Carter, S., van de Ven, C., Kernan, N. A., and Kurtzberg, J., Cord Blood Log CD34+ and CD34+ Subsets (CD38-, CD61+, CD90+) are Significantly Correlated to Log Total CFU, CFU-GEMM, CFU-GM and BFU-E: A Report From The COBLT/NHLBI Program, 2004.
M. S. Cairo, Wagner, E. L., Fraser, J., Cohen, G., van de Ven, C., Carter, S. L., Kernan, N. A., and Kurtzberg, J., Characterization of Banked Umbilical Cord Blood Hematopoietic Progenitor Cells (HPC) and Lymphocyte Subsets (LS) and Correlation with Ethnicity, Birth Weight, Gender and Type of Delivery: A COBLT Study Report, Transfusion, vol. 45, pp. 856-866, 2005.
K. - C. Chang, Der Wang, J. -, Saxon, A., Matthews, A. G., Woody, G., and Hser, Y. - I., Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan., Int J Drug Policy, vol. 43, pp. 1-6, 2017.
H. X. Chen, Gore-Langton, R. E., and Cheson, B. D., Clinical trails referral resource. Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab, Oncology, vol. 15, pp. 1026-36, 2001.
B. D. Cheson, Wilson, W. H., and Phillips, P. H., Clinical Trials Referral Resource. Clinical trials at the Medicine Branch of the NCI-Part II, Oncology, vol. 9, no. 6, pp. 506, 509-510, 1995.
B. D. Cheson, Phillips, P. H., Pluda, J. M., and Christian, M., Clinical Trials Referral Resource. Clinical Trials of Suramin, Oncology, vol. 9, no. 2, p. 161, 163, 1995.
B. D. Cheson and Nelson, A. P., Clinical Trials Referral Resource. Clinical Trials in Adult Acute Myelogenous Leukemia, Oncology, vol. 12, pp. 224-27, 1998.
B. D. Cheson, Foss, F. M., and Phillips, P. H., Clinical Trials Referral Resource. Mycosis Fungoides/Sézary Syndrome, Oncology, vol. 9, no. 7, pp. 645-646, 1995.
B. D. Cheson, Phillips, P. H., and Arbuck, S. G., Clinical Trials Referral Resource. Trials of Topotecan., Oncology, vol. 9, no. 3, pp. 220, 224-226, 228, 1995.
B. D. Cheson, Wittes, R. E., and Phillips, P. H., Clinical Trials Referral Resource. Clinical Trials at the Medicine Branch of the NCI-Part I, Oncology, vol. 9, no. 4, pp. 292-294, 1995.
B. D. Cheson, Arbuck, S. G., and Phillips, P. H., Clinical Trials Referral Resource. Myelodysplastic syndromes., Oncology, vol. 9, no. 9, pp. 821-822, 825, 1995.
B. D. Cheson, Rosenberg, S. A., and Phillips, P. H., Clinical Trials Referral Resource. Clinical Trials at the Surgery Branch of the NCI, Oncology, vol. 9, no. 5, pp. 453-454, 1995.
E. Y. Chew, Clemons, T. E., Peto, T., Sallo, F. B., Ingerman, A., Tao, W., Singerman, L., Schwartz, S. D., Peachey, N. S., and Bird, A. C., Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial, Am J Ophthalmol, vol. 159, no. 4, pp. 659-666.e1., 2015.
E. Y. Chew, Clemons, T. E., Klein, M. L., Klein, B. E. K., Friberg, T., Bressler, S., and Group, A. - R. Eye Diseas, Cognitive function in the Age-Related Eye Disease Study (AREDS), 2004.
T. Clemons, Rankin, M., McBee, W., and Group, A. - R. Eye Diseas, Cognitive Impairment in the Age-Related Eye Disease Study. AREDS Report No. 16, Arch Ophthalmol, vol. 124, pp. 537-543, 2006.
T. E. Clemons and Sperduto, R. D., Cataract Risk Factors in a Subgroup of Patients Age 80 and Older From the Age-Related Eye Disease Study, 2006.
N. C. Close, Hering, B. J., Anand, R., and Eggerman, T. L., (Collaborative Islet Transplant Registry [CITR]), Clinical Transplant, vol. Chapter 9, 2004.
N. C. Close, Hering, B. J., Anand, R., and Eggerman, T. L., Collaborative iIslet Transplant Registry, Clin Transpl, pp. 109-18, 2003.
B. A. Conley, Gore-Langton, R. E., and Cheson, B. D., Clinical trials resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck, Oncology, vol. 14, pp. 553-554559 561, 2000.
M. Abbas Conteh, Goldstein, S. T., Wurie, H. R., Gidudu, J., Lisk, D. Radcliffe, Carter, R. J., Seward, J. F., Hampton, L. M., Wang, D., Andersen, L. E., Arvay, M., Schrag, S. J., Dawson, P., Fombah, A. E., Petrie, C. R., Feikin, D. R., Russell, J. B. W., Lindblad, R., Kargbo, S. A. S., Samai, M., and Mahon, B. E., Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola., J Infect Dis, vol. 217, no. suppl_1, pp. S33-S39, 2018.
J. Copley, Staffeld, C., Lindberg, J., Bailey, C., and Van Veldhuisen, P., Cyclosporine to tacrolimus: rejection, toxicity and cardiovascular risks, 2000.
J. Copley, Staffeld, C., Lindberg, J., Baily, C., and Van Veldhuisen, P., The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity, 1999.
J. B. Copley, Staffeld, C., Lindberg, J., Hansen, A., Bailey, C., Anand, R., and Van Veldhuisen, P., Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts, Transplant Proc, vol. 30, pp. 1254-6, 1998.
L. Corey, McElrath, M. J., Weinhold, K., Matthews, T., Stablein, D., Graham, B., Keefer, M., Schwartz, D., Gorse, G., and Group, theA. I. D. S. Vacci, Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type1 envelope with a combination vaccine regimen, J Infec Dis, vol. 177, pp. 301-9, 1998.